The emerging treatment of this peptide represents a major advance in the management of type 2 diabetes. Unlike existing medications, tirzepatide targets two pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – resulting in enhanced glucose control and possible weight reduction. Researchers are inve